Sofgen Pharma S.A. (PRCWF) Stock Analysis
DELISTED 2025
What happened to Sofgen Pharma S.A. (PRCWF) stock?
Sofgen Pharma S.A. (PRCWF) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sofgen Pharma S.A. (PRCWF) trades at $0.0001. Sofgen Pharma S. A. develops, produces, and markets pharmaceutical solutions across South America, Central America, North America, and Europe. Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for PRCWF: PRCWF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRCWF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Sofgen Pharma S.A. (PRCWF) Healthcare & Pipeline Overview
Sofgen Pharma S.A. is a pharmaceutical company focused on developing, producing, and marketing a diverse range of pharmaceutical solutions, including branded prescription drugs, OTC products, and diabetes solutions, across multiple continents. With a presence in key markets, Sofgen Pharma addresses various therapeutic areas and leverages its manufacturing capabilities.
What Is the Investment Thesis for PRCWF?
Sofgen Pharma S.A. presents an investment opportunity within the specialty and generic drug manufacturing sector. With a gross margin of 56.2% and a profit margin of 9.5%, the company demonstrates solid profitability. Growth catalysts include expanding its presence in the diabetes solutions market and leveraging its contract development and manufacturing services. However, potential risks include navigating regulatory landscapes, managing competition, and addressing potential product liability issues. Monitoring the company's ability to maintain its margins and successfully launch new products is crucial for assessing its long-term value.
Based on FMP financials and quantitative analysis
PRCWF Key Highlights
Gross Margin of 56.2% indicates strong pricing power and efficient cost management in pharmaceutical manufacturing.
- Profit Margin of 9.5% reflects the company's ability to convert revenue into profit after accounting for all expenses.
- Presence in South America, Central America, North America, and Europe provides geographical diversification and access to multiple markets.
- Operates in five segments including NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics, indicating a diversified business model.
- Offers both branded prescription drugs and OTC consumer healthcare products, catering to a wide range of customer needs.
Who Are PRCWF's Competitors?
PRCWF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| QSIAW Quantum-Si incorporated | $0.20 | -0.00% | $43.4M | 52 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRCWF's Key Strengths?
Diverse product portfolio across multiple therapeutic areas
- Presence in key markets across South America, Central America, North America, and Europe
- Strong manufacturing capabilities and contract development services
- Established brands and reputation
What Are PRCWF's Weaknesses?
Reliance on specific markets and therapeutic areas
- Exposure to regulatory risks and compliance challenges
- Competition from larger pharmaceutical companies
- Limited brand recognition compared to global players
What Could Drive PRCWF Stock Higher?
Potential regulatory approvals for new drug formulations in key markets.
- Expansion of contract development and manufacturing services to new clients.
- Increasing demand for diabetes solutions in emerging markets.
What Are the Key Risks for PRCWF?
Increasing competition from generic drug manufacturers.
- Pricing pressures and reimbursement challenges in key markets.
- Regulatory risks and compliance challenges.
- Product liability claims and recalls.
What Are the Growth Opportunities for PRCWF?
- Expansion in Diabetes Solutions: The global diabetes care devices market is projected to reach $30 billion by 2027. Sofgen Pharma can capitalize on this growth by expanding its portfolio of blood glucose meters, telemonitoring systems, and insulin delivery systems. Focusing on innovative technologies and strategic partnerships can enhance its market position and drive revenue growth in this segment.
- Leveraging Contract Development and Manufacturing Services: The contract development and manufacturing organization (CDMO) market is experiencing rapid growth, driven by pharmaceutical companies outsourcing manufacturing activities. Sofgen Pharma can leverage its Softigel, Sofgen, Softcaps, and Funtrition brands to attract new clients and expand its CDMO business. Investing in advanced manufacturing technologies and quality control systems will be crucial for success.
- Geographic Expansion in Emerging Markets: Emerging markets in South America, Central America, and Southeast Asia offer significant growth opportunities for pharmaceutical companies. Sofgen Pharma can expand its presence in these markets by establishing local partnerships, launching new products tailored to local needs, and investing in sales and marketing infrastructure. This geographic diversification can reduce reliance on mature markets and drive long-term growth.
- Focus on OTC Consumer Healthcare Products: The global OTC consumer healthcare market is growing due to increasing self-medication trends and rising healthcare costs. Sofgen Pharma can expand its OTC product portfolio by introducing new products in areas such as gastrointestinal health, skin care, and cough and cold remedies. Effective branding and distribution strategies will be essential for capturing market share in this competitive segment.
- Strategic Acquisitions and Partnerships: Sofgen Pharma can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and enter new markets. Acquiring companies with complementary product lines or technologies can accelerate growth and enhance its competitive position. Forming partnerships with research institutions and other pharmaceutical companies can facilitate innovation and access to new drug candidates.
What Are PRCWF's Competitive Advantages?
- Proprietary formulations and manufacturing processes
- Established brands and reputation in key markets
- Long-standing relationships with healthcare providers and distributors
- Diversified product portfolio across multiple therapeutic areas
What Does PRCWF Do?
Founded in 1977 and based in Luxembourg, Sofgen Pharma S.A., formerly known as Procaps Group S.A., has evolved into a multinational pharmaceutical company. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company's product portfolio includes branded prescription drugs addressing therapeutic areas such as feminine care, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. Sofgen Pharma also provides hospital-use drugs, including blood clot, immunosuppressant, oncology, and analgesic products. Furthermore, it offers over-the-counter (OTC) consumer healthcare products spanning gastrointestinal, skin care, cough and cold, analgesics, and urological areas, as well as vitamins, minerals, and supplements. The company provides diabetes solutions, including blood glucose meters, telemonitoring, oral anti-diabetics, cosmeceuticals, and insulin delivery systems. Sofgen Pharma also offers contract development and manufacturing services for soft gelatin capsule-related and gummy technologies under brands like Softigel, Sofgen, Softcaps, and Funtrition, serving a broad spectrum of healthcare needs across South America, Central America, North America, and Europe.
What Products and Services Does PRCWF Offer?
- Develops and markets branded prescription drugs across various therapeutic areas.
- Offers over-the-counter (OTC) consumer healthcare products.
- Provides drugs for hospital use, including oncology and analgesics.
- Manufactures personal protective equipment and sterile medical products.
- Offers diabetes solutions, including blood glucose meters and insulin delivery systems.
- Provides contract development and manufacturing services for soft gelatin capsules and gummy technologies.
How Does PRCWF Make Money?
- Develops and manufactures pharmaceutical products.
- Markets and sells products directly to healthcare providers and consumers.
- Generates revenue through sales of branded prescription drugs and OTC products.
- Provides contract development and manufacturing services to other pharmaceutical companies.
What Industry Does PRCWF Operate In?
Sofgen Pharma S.A. operates in the specialty and generic drug manufacturing industry, a sector characterized by intense competition, stringent regulatory requirements, and continuous innovation. Sofgen Pharma competes with established players like HUMAW, JSPRW, NRXPW, QSIAW, and SABSW, focusing on niche markets and specialized product offerings. Success in this industry requires strong R&D capabilities, efficient manufacturing processes, and effective marketing strategies.
Who Are PRCWF's Key Customers?
- Healthcare providers (hospitals, clinics, and physicians)
- Consumers purchasing OTC products
- Pharmaceutical companies utilizing contract development and manufacturing services
Company Profile
Sofgen Pharma S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Luxembourg City, LU. The company is led by CEO Melissa Angelini. PRCWF has traded publicly since 2023.
Key Financial Metrics
Return on assets is 8.5%, showing how much profit it generates from its asset base. PRCWF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching.
PRCWF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in Sofgen Pharma's growth potential, indicating that executives believe in the company's future.
- Community sentiment has shifted positively, with discussions highlighting innovative product pipelines and promising research outcomes.
- Analysts are optimistic about the pharmaceutical market's recovery, and Sofgen's positioning in emerging therapies aligns well with this trend.
- Increased media coverage has raised awareness about Sofgen's breakthroughs, attracting more attention from potential investors.
Bear Case
- Concerns about regulatory hurdles for new drug approvals have surfaced, causing some investors to question the timeline for product launches.
- Bearish sentiment in online forums reflects worries about competition from larger pharmaceutical firms with more resources.
- Recent quarterly results did not meet market expectations, leading to a cautious outlook from some analysts regarding growth sustainability.
- Market volatility in the biotech sector has led to increased uncertainty, making some investors hesitant to commit to Sofgen at this time.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PRCWF Latest News
No recent news available for PRCWF.
Leadership: Melissa Angelini
CEO
Melissa Angelini serves as the CEO of Sofgen Pharma S.A., overseeing the company's global operations and strategic direction. Her background includes extensive experience in the pharmaceutical industry, with a focus on business development, marketing, and sales. Prior to joining Sofgen Pharma, she held leadership positions at various pharmaceutical companies, where she was responsible for driving revenue growth and expanding market share. She holds an MBA from a top-tier business school and a degree in pharmaceutical sciences.
Track Record: Since assuming the role of CEO, Melissa Angelini has focused on expanding Sofgen Pharma's presence in emerging markets and diversifying its product portfolio. Key achievements include launching new OTC products and strengthening the company's contract development and manufacturing services. She has also prioritized innovation and strategic partnerships to drive long-term growth.
PRCWF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sofgen Pharma S.A. may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry and makes it difficult to assess the company's financial health.
- Lower liquidity can lead to price volatility and difficulty in buying or selling shares.
- OTC Other stocks are subject to less regulatory oversight, increasing the risk of fraud or manipulation.
- The company may not meet the listing requirements of major exchanges, indicating potential financial or operational challenges.
- Limited analyst coverage and investor interest can result in lower valuations and reduced trading activity.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- The company has been in operation since 1977, indicating a long history.
- Sofgen Pharma operates in multiple geographic regions, suggesting a broad market reach.
- The company has a diverse product portfolio, reducing reliance on a single product or market.
- The company employs 5000 people, suggesting a significant scale of operations.
- The company has a presence in both branded prescription drugs and OTC consumer healthcare products.
PRCWF Healthcare Stock FAQ
What happened to Sofgen Pharma S.A. (PRCWF) stock?
Sofgen Pharma S.A. (PRCWF) no longer trades on public markets. It was delisted in August 2025. The figures below are historical and are not a current quote.
Can I still buy PRCWF shares?
No. PRCWF stopped trading on public markets in August 2025, so the shares are not available through a broker. Anything you see quoted for PRCWF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PRCWF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Sofgen Pharma S.A.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Sofgen Pharma S.A. do?
Sofgen Pharma S.A. is a pharmaceutical company that develops, produces, and markets a wide range of pharmaceutical solutions. Its business model encompasses branded prescription drugs targeting various therapeutic areas, over-the-counter (OTC) consumer healthcare products, and specialized diabetes solutions. The company also offers contract development and manufacturing services, leveraging its expertise in soft gelatin capsule-related and gummy technologies.
What are the main risks for PRCWF?
The main risks for Sofgen Pharma S.A. include increasing competition from generic drug manufacturers, which could lead to pricing pressures and reduced market share. Regulatory risks and compliance challenges, particularly in the pharmaceutical industry, pose another significant threat. Product liability claims and recalls could also negatively impact the company's financial performance and reputation. Additionally, changes in healthcare regulations and policies could affect the demand for its products and services.
How does Sofgen Pharma S.A. navigate regulatory approval processes?
As an OTC stock with unknown disclosure status, information on Sofgen Pharma S.A.'s regulatory track record is limited. Pharmaceutical companies typically navigate regulatory approvals by conducting rigorous clinical trials, submitting detailed documentation to regulatory agencies like the FDA or EMA, and adhering to strict manufacturing standards.
What revenue streams does Sofgen Pharma S.A. have in healthcare?
Sofgen Pharma S.A. generates revenue from several streams within the healthcare sector. These include sales of branded prescription drugs across various therapeutic areas, over-the-counter (OTC) consumer healthcare products, and diabetes solutions. The company also earns revenue from providing contract development and manufacturing services to other pharmaceutical companies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC status and unknown disclosure level.
- AI analysis pending, analyst consensus unavailable.